Needham Reiterates Buy on Taysha Gene Therapies, Maintains $5 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Gil Blum has reiterated a Buy rating on Taysha Gene Therapies (NASDAQ:TSHA) and maintained a $5 price target.

February 29, 2024 | 8:02 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Gil Blum reiterates a Buy rating on Taysha Gene Therapies with a $5 price target.
The reiteration of a Buy rating and maintenance of a $5 price target by a reputable analyst like Gil Blum from Needham is likely to instill confidence among investors and could positively influence Taysha Gene Therapies' stock price in the short term. Analyst ratings, especially from well-regarded financial institutions, can significantly impact investor sentiment and stock prices.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100